Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00362739 · ClinicalTrials.gov registry record

Blood Collection From Individuals With Lung Disease for Genetic Studies

A clinical trial, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
3,087
Enrollment target

NCT00362739: Completed study, sponsored by Weill Medical College of Cornell University.

NCT00362739 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 3,087 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00362739 has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
3,087 participants
Enrollment target

Study Summary

This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, and lung cancer.

Trial Details

FieldValue
Enrollment Target 3,087 participants
Start Date 2005-09
Est. Completion 2015-08

What the finished NCT00362739 record still lists

NCT00362739 is an observational study that tracks outcomes without assigning an intervention. Its 3,087 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00362739 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00362739 about?

NCT00362739 is a clinical study titled "Blood Collection From Individuals With Lung Disease for Genetic Studies". This is a research study where researchers are collecting blood to evaluate the genetic characteristics of individuals with chronic lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, and lung cancer.

What is the current status of trial NCT00362739?

This trial is currently completed. The enrollment target is 3,087 participants. The study started on 2005-09. Estimated completion is 2015-08.

Who is sponsoring clinical trial NCT00362739?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05534243 · 3,090 participants · NA

    The ED-AWARENESS-2 Trial

  • NCT06667700 · 3,082 participants · Phase 3

    A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

  • NCT04722822 · 3,100 participants · NA

    The HPV 9-10 Trial: Early Initiation of HPV Vaccination

  • NCT05051722 · 3,110 participants

    Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00362739, the US trial registry maintained by the National Library of Medicine. NCT00362739 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.